BHIC to Buy Vitalcore and 40% Platform Stake for 450,000 Restricted Shares
BHIC has more than doubled off its 52-week low of $0.52 on light trading volume (0.3× avg).
Summary
BioScience Health Innovations agreed to buy all of Vitalcore and 40% of a customer platform with roughly 15,000 active customers and more than $5.0M in sales so far in 2026. The platform stake costs 450,000 restricted shares; Vitalcore requires no additional stock. The target audience is real, but the release gives no profitability, retention or conversion data, and neither deal has closed. For a company that just posted a $186K quarterly loss on revenue down 41% with negative operating cash flow, this is a meaningful strategic bet on a micro-cap balance sheet.
At the time of this announcement, BHIC was trading at $5.49 on OTC in the Life Sciences sector, with a market capitalization of approximately $64.5M. The 52-week trading range was $0.52 to $72.00. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: Wiseek News.